Navigation Links
New Study Offers More Than a Decade of Evidence for Minimally-Invasive Surgery to Treat Female Incontinence
Date:9/8/2008

Results add to body of clinical evidence demonstrating the efficacy and

safety of synthetic mesh slings for treatment of stress urinary

incontinence in women.

SOMERVILLE, N.J., Sept. 8 /PRNewswire/ -- A new study published in the August issue of International Urogynecology Journal analyzes data of an 11-year follow up study on the safety and effectiveness of tension-free vaginal tape (TVT) as a treatment for stress urinary incontinence (SUI) in women. Researchers followed women treated with GYNECARE TVT(TM) Retropubic System Tension-free Support for Incontinence and found that after 11 years, 90% were objectively cured and 97% considered themselves subjectively cured or improved. This study represents the most extensive follow up for modern mid-urethral sling operations to date.

The three-center prospective observational cohort study led by Professor Carl G. Nilsson, Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Finland, reports on 90 women suffering from urinary stress incontinence who were treated with GYNECARE TVT. Pre-operative assessment included a 24-hour pad test, a stress test, physical examination and a visual analog scale for assessing how bothersome the condition was to each patient. Of the original cohort, 69 women were available for post-operative follow-up 11.5 years after surgery. These women were evaluated using a stress test, a pad test, the patient's overall impression of the cure and a questionnaire administered to assess the patient's quality of life. More than 11 years after surgery, 97% of women assessed subjectively considered themselves cured or improved and researchers determined that 90% of patients were objectively cured based on 24-hour pad tests and stress tests.

"Our results substantiate the evidence showing that the TVT procedure is a safe, effective solution that offers excellent long-term cure rates for women suffering with SUI," said Professor Nilsson. "We are encouraged by the fact that we saw no reports of adverse effects such as tape erosion or tissue reactions found during follow up and continue to believe that the TVT procedure represents a significant advance in the treatment of female SUI."

SUI, a condition that affects more than 13 million women in the United States, is the involuntary leakage of urine during routine activities that put pressure on the bladder or urethra, such as laughing, sneezing or coughing. It can be an embarrassing problem that women are hesitant to bring up with their doctor and as a result, only one in 12 women seeks treatment.

To date, more than one million women worldwide have been treated with the GYNECARE TVT family of products, helping to restore their quality of life.

About GYNECARE TVT

The minimally-invasive GYNECARE TVT* Tension-free Support for Incontinence device uses a mesh sling to provide support to the middle of the urethra, the section that is strained during physical activities. This positioning of the device provides support only when needed and creates a "tension-free" treatment solution that reduces the risk of over-correcting.

As with any suspension surgery, this procedure should not be performed in pregnant patients. Additionally, because the PROLENE polypropylene mesh will not stretch significantly, it should not be performed in patients with future growth potential including women with plans for future pregnancy. Although rare, complications associated with the device include injury to blood vessels or nerves, difficulty urinating and bladder and bowel injury.

The family of GYNECARE TVT products is marketed by ETHICON Women's Health & Urology, a division of ETHICON, INC., a Johnson & Johnson company.

About ETHICON Women's Health and Urology

ETHICON Women's Health & Urology offers treatment solutions for a range of common, female pelvic health disorders. The technologies are marketed under the GYNECARE family of brands and include treatments for menorrhagia (heavy periods), fibroids, stress urinary incontinence and pelvic organ prolapse. ETHICON Women's Health & Urology is a division of ETHICON, Inc, a Johnson & Johnson company. For more information visit http://www.gynecare.com.


'/>"/>
SOURCE ETHICON Women's Health & Urology
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Electronic Brachytherapy a Viable Option for Early Stage Breast Cancer, According to Study Presented at ASCO Breast Cancer Symposium
2. Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes
3. Study Suggests a Possible Way to Offset Chemobrain Memory Loss
4. Cytopia Commences Second Phase II Study in Brain Cancer
5. QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
6. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
7. CDC Misses Target With Flawed MMR/Autism Study
8. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
9. Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
10. Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch
11. Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ITL Limited, ( ASX : ITD ), une société de ... excellents résultats semestriels clos le 31 décembre 2016 par ... « Résultats et mise à jour sur la croissance biomédicale ... Faits marquants Bénéfice ... hausse de 104 %) Bénéfice par action ...
(Date:2/24/2017)... 23, 2017 Non-alcoholic steatohepataitis (NASH) ... various drugs being developed for the treatment ... drugs that are in various phases of ... focuses on novel pharmacologic drugs & regenerative ... therapies, recombinant proteins and RNA-based therapeutics, but ...
(Date:2/24/2017)... Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology ... it has acquired exclusive worldwide rights to develop, ... HDAC inhibitor targeting hematological and solid tumors. ... 1 and 2 clinical trials of Abexinostat in ... have already been completed, demonstrating that Abexinostat is ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... February 26, 2017 , ... ODH, Inc.™ announced today it will exhibit ... Sheraton Pentagon City Hotel in Arlington, VA. ODH’s director of medical strategy, Candace Saldarini, ... to improve Medicaid population health management. , ODH will also have an exhibit booth ...
(Date:2/25/2017)... ... February 25, 2017 , ... FCPX users now have the ability to ... Studios. With ProSharpen Color users have total control over sharpening amount, sharpening radius, threshold, ... With color spectrum tools users can visually see the color range effected with ease ...
(Date:2/24/2017)... ... ... Only two months after the official release of The Private Collection – Edition 2017 ... initiated a second print-run of its lavish luxury travel coffee table book. , ... in at more than six kilos, retails at EUR 1,000 per copy and is ...
(Date:2/24/2017)... ... , ... Dr. Ronald E. Hawkins, vice president for academic ... A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new dean of ... comes to Liberty from the Ohio University Heritage College of Osteopathic Medicine (OU-HCOM), ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... and hearing disabilities, it is so critically important that we all are aware ... That is why Mediaplanet is proud to announce the launch of its newest ...
Breaking Medicine News(10 mins):